Topics

Eisai withdraws weight loss drug Belviq after FDA highlights cancer risk

05:21 EST 14 Feb 2020 | Pharmafile

The FDA has requested that Eisai withdraw its weight loss drug Belviq (lorcaserin) and Belviq XR from the US market after clinical trial data indicated that those receiving the drug exhibited an increased incidence of cancer.

The findings arose from a review of trial results last month, from which it was determined that the "potential risk of cancer associated with the drug outweighs the benefit of treatment," according to the FDA's Center for Drug Evaluation and Research, Janet Woodcock.

read more

Original Article: Eisai withdraws weight loss drug Belviq after FDA highlights cancer risk

NEXT ARTICLE

More From BioPortfolio on "Eisai withdraws weight loss drug Belviq after FDA highlights cancer risk"

Quick Search